Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: J Pediatr. 2016 Aug 30;178:206–213. doi: 10.1016/j.jpeds.2016.08.017

Table 3.

Characteristics of HBV-Infected Alaska Native Males Aged <40 Years and Females Aged <50 Years with HCC — Alaska, 1982–2012.

Patient No. Age range (years)a Sex HCC FHb Cirrhosisa,c HBV genotype Tumor stagea,d Initial HCC Treatment HCC recurrence Time to HCC recurrence (years) Survival after initial HCC diagnosis (years)
1 18–50 F No No A2 Late Resection Yes <5 1–4
2 18–40 M No Yes D Late None No <1
3 5–17 M No Unknown D Late None No <1
4 5–17 M No No F1 Early Resection Yes >10 >10
5 5–17 F Yes No F1 Early Resection Yes >10 >10
6 18–50 F Yes No F1 Early TAREe No 1–4
7 18–50 F Yes Yes F1 Late Resection Yes <5 5–10
8 18–40 M Yes No F1 Early Resection Yes >10 >10
9 18–40 M No No F1 Late Resection No >10
10 18–40 M Yes No F1 Early Resection Yes 5–10 >10
11 18–50 F No No F1 Early Resection No >10
12 5–17 M No No F1 Early Resection No >10
13 18–40 M No Yes F1 Early Resection Yes 5–10 >10
14 18–50 F No Yes F1 Early Resection Yes <5 >10
15 18–50 F Yes Unknown F1 Late TACE Yes 1–4
16 5–17 M No No F1 Early Resection No >10
17 18–40 M Yes No F1 Early Resection Yes <5 1–4
18 5–17 M Yes Yes F1 Early Ablation Yes 5–10 >10
19 18–40 M No No F1 Early Resection No >10
20 18–40 M Yes Yes F1 Early Resection Yes <5 1–4
21 5–17 M No No F1 Early Resection No >10
22 18–40 M No No F1 Late Resection Yes <5 5–10

Abbreviations: FH, family history; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; No., number; TACE, transarterial chemoembolization; TARE, transarterial radioembolization

a

Age range at time of initial HCC diagnosis presented rather than exact age in order to protect study participants’ confidentiality

b

First-degree relative with HCC

c

Ishak fibrosis score = 5–6 on liver histology

d

Early-stage tumor if single tumor ≤5 cm in diameter or ≤3 tumors ≤3 cm in diameter; otherwise late-stage tumor. Tumor size unknown for persons refusing additional evaluation.

e

Person progressed from early- to late-stage between diagnosis and treatment

f

Bold indicates alive at by end of study period; all except one deceased person died of HCC